BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,070 filers reported holding BAXTER INTL INC in Q3 2021. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $258,496 | -35.1% | 5,072 | -30.7% | 0.10% | -42.2% |
| Q3 2022 | $398,000 | -21.0% | 7,322 | -6.6% | 0.17% | -14.0% |
| Q2 2022 | $504,000 | -27.6% | 7,841 | -12.6% | 0.19% | -10.2% |
| Q1 2022 | $696,000 | -14.4% | 8,976 | -6.3% | 0.22% | -13.3% |
| Q4 2021 | $813,000 | +8.0% | 9,576 | +2.8% | 0.25% | +0.8% |
| Q3 2021 | $753,000 | -2.1% | 9,316 | -2.5% | 0.25% | -3.5% |
| Q2 2021 | $769,000 | -8.5% | 9,556 | -4.0% | 0.26% | -22.5% |
| Q1 2021 | $840,000 | +5.1% | 9,956 | 0.0% | 0.33% | +3.8% |
| Q4 2020 | $799,000 | -0.2% | 9,956 | -2.4% | 0.32% | -16.8% |
| Q3 2020 | $801,000 | -12.9% | 10,206 | -5.5% | 0.38% | -10.6% |
| Q2 2020 | $920,000 | -11.5% | 10,800 | -3.4% | 0.43% | -26.0% |
| Q1 2020 | $1,039,000 | +5.3% | 11,175 | -5.3% | 0.58% | +22.8% |
| Q4 2019 | $987,000 | -6.8% | 11,805 | -2.5% | 0.47% | -10.3% |
| Q3 2019 | $1,059,000 | +6.9% | 12,105 | 0.0% | 0.52% | -0.9% |
| Q2 2019 | $991,000 | +2377.5% | 12,105 | +2321.0% | 0.53% | +2300.0% |
| Q1 2019 | $40,000 | +25.0% | 500 | 0.0% | 0.02% | +10.0% |
| Q4 2018 | $32,000 | -15.8% | 500 | 0.0% | 0.02% | +5.3% |
| Q3 2018 | $38,000 | – | 500 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Point | 41,000,000 | $2,482,140,000 | 22.00% |
| THUNDERBIRD PARTNERS LLP | 1,711,643 | $103,623,000 | 12.17% |
| SECTOR GAMMA AS | 1,070,333 | $64,798,000 | 9.42% |
| Veritas Asset Management LLP | 10,179,102 | $616,243,000 | 4.81% |
| 13D Management LLC | 194,807 | $11,794,000 | 4.18% |
| Progressive Investment Management Corp | 78,316 | $4,741,000 | 3.69% |
| Aristotle Capital Management, LLC | 6,846,307 | $414,476,000 | 3.46% |
| ARGENT CAPITAL MANAGEMENT LLC | 1,394,075 | $84,397,000 | 3.37% |
| Lipe & Dalton | 80,073 | $4,848,000 | 3.14% |
| PURA VIDA INVESTMENTS, LLC | 125,000 | $7,568,000 | 3.00% |